TranscriptsNov 11, 2026, 6:59 PM ETElicio Therapeutics, Inc. (ELTX) StockSA Transcripts162.98K FollowersElicio Therapeutics, Inc. (ELTX) Discusses Camupepimut Development in Neoadjuvant and Metastatic Pancreatic Cancer November 11, 2026 2:30 PM ESTCompany ParticipantsChristopher Haqq - Executive VP, Head of Research & Development and Chief Medical OfficerConference Call ParticipantsKevin SoaresEileen O'ReillyRobert Burns - H.C. Wainwright & Co, LLC, Research DivisionKevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research DivisionBoris Peaker - JonesTrading Institutional Services, LLC, Research DivisionPresentationOperatorGood afternoon, everyone, and welcome to the Elicio Therapeutics Virtual KOL Event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Elicio website following the conclusion of the event.I'd now like to turn the call over to Dr. Chris Haqq, Chief Executive Officer (sic) [ Chief Medical Officer ] and Head of Research and Development at Elicio Therapeutics. Please go ahead, Chris.Christopher HaqqExecutive VP, Head of Research & Development and Chief Medical OfficerGreat. Thank you very much. It's a pleasure today to welcome you to our discussion of neoadjuvant and metastatic applications of camupepimut, the clinical development in KRAS-mutated pancreatic ductal adenocarcinoma.I'll introduce here just that we will today be making forward-looking statements. And if you have any further questions about that, please refer to the Elicio website.Today, in our agenda, we're very privileged to have 2 speakers that are immensely knowledgeable in the treatment of pancreatic cancer with Dr. Kevin Soares, Assistant Attending Surgeon on the Hepatopancreatobiliary Service at Memorial Sloan Kettering Cancer Center. And Dr. Soares is the principal investigator of the neoadjuvant Phase 1 study incorporating camupepimut, and he'll speak about that as we've received so many questions about the recent start-up of that study.In addition, it's a pleasure to be joined today with Dr. Eileen O'Reilly. Eileen is the Winthrop RockefellerRead more current ELTX analysis and newsView all earnings call transcriptsComments